Passage BIO, Inc.

Passage BIO, Inc.

Passage BIO, Inc. was founded as a biotechnology company dedicated to developing gene therapies for patients with rare diseases. The firm's platform utilizes AAV vectors to deliver genetic payloads, with clinical programs addressing conditions like Duchenne muscular dystrophy and Batten disease. Its therapeutics remain in early-stage clinical trials, with no approved products to date. Strategically, Passage BIO focuses on pre-clinical and clinical development, operating a pipeline of wholly-owned candidates and partnerships. The company's asset class mix includes research-stage assets and potential regulatory milestones, though it does not deploy capital as an investment firm. Geographic footprint centers on the United States, with clinical trial sites and research operations located domestically. Passage BIO maintains a lean operational structure typical of early-stage biotechs, with a team size and financial details not publicly disclosed in available sources. No recent operational events from the last 24 months have been verified. The firm may have philanthropic or research collaborations, but these are not confirmed in public records. The structural differentiator for Passage BIO is its pure-play gene therapy focus, which distinguishes it from broader biotech firms. However, without public financial disclosures or verifiable leadership, the firm's architecture remains opaque, limiting assessment of its investment or ownership structure.